Denali Therapeutics is a pre-commercial biotech focused on CNS diseases, with its value hinging on pipeline execution. The company's financials reveal a sustained and accelerating cash burn, with quarterly operating losses exceeding $130M and free cash flow de...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.68-32.5% vs -$0.51 | $4M+67.3% vs $2M |
Q2 2026 May 7, 2026 | -$0.69+5.5% vs -$0.73 | — vs $3M |
Q2 2026 May 5, 2026 | -$0.69+5.5% vs -$0.73 | — vs $3M |
Q1 2026 Feb 26, 2026 | -$0.73+2.7% vs -$0.75 | — vs $3M |
Engineers Gate Manager LP lifted its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 256.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,430 shares of the company's stock after purchasing an additional 41,320 shares during the
WINTON GROUP Ltd decreased its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 80.2% during the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 14,100 shares of the company's stock after selling 57,079 shares during the period. WINTON GROUP Ltd's holdings in Denali Therapeutics were worth $363,000
Altimmune (NASDAQ: ALT - Get Free Report) and Denali Therapeutics (NASDAQ: DNLI - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation. Analyst Ratings This is a breakdown of current recommendations
Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark DNLI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Denali Therapeutics Inc. (DNLI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.46 | $3.25B | -6.89 | — | — | -45.69% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $7.83 | $505.2M | -6.12 | -0.3% | 2.94% | 1.91% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $138.70 | $8.92B | -67.66 | -89.41% | 29.4% | 12.03% | — |
Denali Therapeutics Inc. (DNLI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Denali Therapeutics Inc. (DNLI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 28, 2026·SEC
Jun 18, 2026·SEC
Get notified when DNLI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Denali Therapeutics Inc. (DNLI) stock FAQ — growth, dividends, profitability & financials explained
Denali Therapeutics Inc. (DNLI) reported $3.6M in revenue for fiscal year 2025.
Denali Therapeutics Inc. (DNLI) reported a net loss of $511.5M for fiscal year 2025.
Denali Therapeutics Inc. (DNLI) has a return on equity (ROE) of -45.7%. Negative ROE indicates the company is unprofitable.
Denali Therapeutics Inc. (DNLI) had negative free cash flow of $571.1M in fiscal year 2025, likely due to heavy capital investments.
